A New Therapeutic Candidate for Cardiovascular Diseases: Berberine

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Natural Products

Background:

• Cardiovascular diseases (CVD) remain the primary cause of mortality worldwide.
• Current CVD treatments exhibit limited efficacy and potential adverse effects, leading to poor patient prognoses.
• Berberine (BBR), a natural compound with a history of use for infections, is emerging as a potential therapeutic agent for CVD.

Purpose of the Study:

• To systematically review recent pharmacological research on berberine (BBR) for cardiovascular disease (CVD) treatment.
• To explore the cardiovascular protective mechanisms of BBR across various CVD conditions.
• To evaluate BBR as a prospective therapeutic option for CVD management.

Main Methods:

• Literature review of recent pharmacological studies on BBR and CVD.
• Analysis of research investigating BBR's multi-target pharmacological actions.
• Synthesis of evidence on BBR's efficacy and safety in preclinical and clinical settings for CVD.

Main Results:

• Berberine (BBR) demonstrates significant therapeutic potential across a spectrum of cardiovascular diseases (CVD), including arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis, cardiomyopathy, and heart failure.
• Pharmacological research supports the multi-target cardiovascular protective mechanisms of BBR.
• Evidence indicates BBR's effectiveness and safety profile, supporting its use in CVD treatment.

Conclusions:

• Berberine (BBR) is a promising natural compound for the prevention and treatment of cardiovascular diseases (CVD).
• Further research into BBR's mechanisms and clinical applications could lead to novel therapeutic strategies for CVD.
• BBR represents a viable and potentially safer alternative or adjunct therapy for managing cardiovascular conditions.